Abstract:Jinrui Ji, 1, 2, &ast Xiaoyun Wei, 1, 2, &ast Dongyun Wan, 1, 2, &ast Lei Wu, 1, 2, &ast Guangyao Chen, 1, 3, &ast Hengliang Liu 1, 2, &ast 1 Clinical Medical Department, Faculty of Medicine, Henan University of Traditional Chinese Medicine, Zhengzhou, 450000, People's Republic of China; 2 Department of Cardiology, People's Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou, 450000, People's Republic of China; 3 Zhengzhou Institute of Gastroenterology, People's Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou, 450000, People's Republic of China &astThese authors contributed equally to this work Correspondence: Hengliang Liu, Henan University of Traditional Chinese Medicine, No. 33, Huanghe Road, Jinshui District, Zhengzhou, Henan Province, 450000, People's Republic of China, Tel/Fax +86 0371-67077158, Email Purpose: This study investigated the influence of plasma proprotein convertase subtilisin/kexin 9 (PCSK9) levels on the degree of atherosclerosis and major adverse cardiovascular and cerebrovascular events (MACCE) in older adults with non-alcoholic fatty liver disease. Methods: The degree of atherosclerosis severity was assessed by the standard Gensini score quartile method. According to the degree of atherosclerosis, patients were divided into mild (0– 24 points; n=84), moderate (25– 53 points; n=86), and severe groups (≥ 54 points; n=84) and then categorized as MACCE (n=30) or non-MACCE (n=224) according to 6-month follow-up data. The patients' age, sex, smoking history, medical history, and early morning fasting venous blood, for measuring biochemical indexes, were collected. Clinical data were compared between groups and the relationship between Gensini scores and PCSK9 was evaluated. Results: Compared with the mild group, the moderate and severe groups had higher high-sensitivity C-reactive protein(hs-CRP), PCSK9, triglycerides(TG), low-density lipoprotein cholesterol (LDL-C), and lipoprotein(a)[Lp(a)] levels and lower high-density lipoprotein cholesterol(HDL-C) levels (all P< 0.05). Moreover, PCSK9 positively correlated with Gensini scores (r=0.657, P< 0.01). The MACCE and non-MACCE groups had significantly different ages, statin use, Gensini scores, PCSK9, and LDL-C (all P< 0.05). Multi-factorial Cox risk regression analysis showed the Gensini score (HR=1.018, 95% CI: 1.006~1.029) and PCSK9 (HR=1.147, 95% CI: 1.038~1.287) were independent risk factors for MACCE. Conclusion: The Gensini score and PCSK9 levels can be used as predictive indicators for the degree of illness and occurrence of MACCE in older NAFLD patients. Keywords: older adults, non-alcoholic fatty liver disease, proprotein convertase subtilisin/kexin 9, atherosclerosis, major adverse cardiovascular and cerebrovascular events Between population aging, the obesity epidemic, and the effective control of viral hepatitis, non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease worldwide, with increasing clinical complications, economic burden, and impact on the quality and longevity of patients' lives. 1,2 NAFLD is intrinsically linked to metabolic and cardiovascular disease and may be involved in cardiovascular disease pathogenesis by inducing insulin resistance, atherogenic dyslipidemia, and the release of systemic inflammatory mediators, coagulation mediators, and oxidative stressors. 3–5 Major adverse cardiovascular and cerebrovascular events (MACCE) are the leading cause of death in patients with NAFLD, 6,7 especially in older NAFLD patients. The risk of cardiovascular events in this patient subgroup needs to be regularly assessed, even when their body mass index is normal. Detecting MACCE in older NAFLD patients at an early stage and intervening as early as possible is the key to improving their quality of life. 8 Plasma proprotein convertase subtilisin/kexin 9 (PCSK9) is a member of the proprotein convertase family, and its functional changes are involved in the progression of cardiovascular disease and atherosclerosis. 9 Studies have found that higher serum PCSK9 levels are associated with higher Gensini coronary artery lesion scores, more severe atherosclerosis, and a greater risk of MACCE. 10,11 To our knowledge, the relationship between PCSK9 levels and the risk of MACCE in older NAFLD patients is unclear. In this study, we investigated the relationship between serum PCSK9 levels and the degree of atherosclerosis in patients with NAFLD and the predictive -Abstract Truncated-

PCSK9 rs11591147 R46L loss‐of‐function variant protects against liver damage in individuals with NAFLD

Analysis of steatosis biomarkers and inflammatory profile after adding on PCSK9 inhibitor treatment in familial hypercholesterolemia subjects with nonalcoholic fatty liver disease: A single lipid center real-world experience

Nonalcoholic Fatty Liver Disease Risk and Proprotein Convertase Subtilisin Kexin 9 in Familial Hypercholesterolemia Under Statin Treatment

PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans

The rs2294918 E434K variant modulates PNPLA3 expression and liver damage.

Peroxisome Proliferator-Activated Receptor Γ Coactivator 1α Maintains NAD+ Bioavailability Protecting Against Steatohepatitis

Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Activation Modulating ox-LDL Pathways

PCSK9 and Lipid Metabolism: Genetic Variants, Current Therapies, and Cardiovascular Outcomes

Assessing the Impact of PCSK9 and HMGCR Inhibition on Liver Function: Drug-Target Mendelian Randomization Analyses in Four Ancestries

Transmembrane 6 Superfamily Member 2 Gene Variant Disentangles Nonalcoholic Steatohepatitis from Cardiovascular Disease

Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9

Predictive Value of Plasma PCSK9 Levels for Degree of Atherosclerosis and Major Adverse Cardiovascular and Cerebrovascular Events in Older Adult Patients with Non-Alcoholic Fatty Liver Disease

Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort☆

Metabolomic Consequences of Genetic Inhibition of PCSK9 Compared with Statin Treatment.

Proprotein convertase subtilisin/kexin type 9 deficiency in extrahepatic tissues: emerging considerations

Promoting genetics in non-alcoholic fatty liver disease: Combined risk score through polymorphisms and clinical variables

Loss-of-function genomic variants with impact on liver-related blood traits highlight potential therapeutic targets for cardiovascular disease

Effect of the PCSK9 R46L genetic variant on plasma insulin and glucose levels, risk of diabetes mellitus and cardiovascular disease: A meta-analysis

Inhibition of Proprotein Convertase Subtilisin/Kexin Type 9 Ameliorates Liver Fibrosis Via Mitigation of Intestinal Endotoxemia

PNPLA3 rs738409, age, diabetes, sex, and advanced fibrosis jointly contribute to the risk of major adverse liver outcomes in metabolic-associated steatotic liver disease

New target-HMGCR inhibitors for the treatment of primary sclerosing cholangitis: A drug Mendelian randomization study